Mustang Bio Q2 net loss $16.2M; completes uBriGene asset sale for $6M

MUSTANG BIO, INC.

2023-Q2 EPS reported -$4.06

Cash and equivalents $16.1M at June 30, down from $76.7M at Dec 31, 2022, reflecting Runway loan repayment.
Net loss $16.2M ($2.00/share) vs $19.1M ($2.50/share) in Q2 2022.
Closed amended asset sale to uBriGene for $6M upfront; expects $28M annual cost reduction.
Lead CAR T MB-106 shows 83% response in WM cohort; 95% ORR in FL cohort.
First pivotal Phase 2 WM patient expected Q1 2024; additional multicenter data in Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MUSTANG BIO, INC. reported the second quarter ended June 30, 2023 results: net income Net loss attributable to common stockholders was $16.2 million, or $2.00 per share.

Period: the second quarter ended June 30, 2023
Net income: Net loss attributable to common stockholders was $16.2 million, or $2.00 per share
Result: reported results

Exact text from the filing

On August 14, 2023, Mustang Bio, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

MUSTANG BIO, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-014849

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.